GlassScriptPhysician profile
Madhavi Averneni
NPI 1710171954
$3,206.17
in general payments reported to CMS, 2019-2025
35 companies · $14.46 in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $366 · 2021: $668 · 2022: $1,254 · 2023: $376 · 2024: $98.80 · 2025: $14.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $489.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $500.03 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $321.84 | 2020-2022 | |
| Amgen INC. | $296.94 | 2019-2024 | Evenity, Prolia |
| Lilly USA, LLC | $252.50 | 2020-2023 | Mounjaro, Jardiance, Emgality |
| Sanofi-Aventis U.S. LLC | $237.30 | 2019-2022 | |
| Dexcom, INC. | $214.24 | 2020-2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $153.91 | 2021-2024 | Skyrizi, Ubrelvy |
| Ucb, INC. | $133.84 | 2020-2024 | Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.85 | 2019-2022 | |
| Janssen Biotech, INC. | $103.92 | 2021-2022 | |
| Glaxosmithkline, LLC. | $75.15 | 2020-2025 | Shingrix |
| Esperion Therapeutics, INC. | $71.43 | 2021-2022 | |
| Eisai INC. | $63.06 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $60.64 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $58.82 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $58.39 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $57.58 | 2021-2022 | |
| Medtronic, INC. | $56.07 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $44.70 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.02 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.92 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $32.84 | 2022 | |
| Abbott Laboratories | $29.28 | 2023 | Proclaim, Freestyle Libre 3 |
| Radius Health, INC. | $25.17 | 2023 | Tymlos |
| Kowa Pharmaceuticals America, INC. | $23.80 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.17 | 2022 | |
| Lifescan, INC. | $15.66 | 2022 | |
| Irhythm Technologies, INC. | $15.47 | 2024 | Zio Monitor, Zio Xt Patch |
| Amarin Pharma, INC. | $14.48 | 2021 | |
| Pfizer INC. | $13.94 | 2020 | |
| Ani Pharmaceuticals, INC. | $13.64 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $12.87 | 2020 | |
| Merck Sharp & Dohme LLC | $12.18 | 2019 | |
| Astellas Pharma US INC | $11.45 | 2019 | |
| Medtronic Minimed, INC. | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhavi Averneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.